Why Minnesota Companies Are Looking Down Under 

Local innovators like Imricor (ASX:IMR) Medical Systems and Saluda (ASX:SLD) Medical have already tapped into the Australian market to fund their next phases of growth. Australia offers a deep pool of healthcare-focused institutional capital (backed by a $3.5T+ superannuation system) tailored for early-to-mid commercialization stage companies.

What You'll Gain:

·       The "NASDAQ Gap" Solution: How the ASX provides public market liquidity without the massive market-cap demands and compliance overhead of U.S. exchanges.

·       Investor & Valuation Dynamics: What Australian investors look for in U.S. healthcare and biotech platforms.

·       A Firsthand Case Study: Hear directly from  President &CEO, Imricor Medical Systems a U.S. healthcare executive who navigated the ASX listing process, raised capital, and continues to operate successfully as a public company.

·       Strategic Value for Investors: How VCs, PE funds, and advisors can leverage the ASX as a viable liquidity or follow-on financing pathway for portfolio companies.

Who Should Attend: Founders, CEOs, CFOs, healthcare investors (VC/PE), and strategic board advisors. 

 

Note: Companies do not need to be actively preparing for an IPO or currently operating in Australia to attend. This is an educational & informative executive session.